Mitchell C. C. Liu
Clinical Professor

British Columbia
Cancer Agency –
Vancouver Centre

Our group has demonstrated the efficacy of SBRT through clinical trials such as SC.24, SABR-COMET, and SABR-5.
As radiation oncologists, it is our responsibility to address each clinical question step by step.
The topic of re-irradiation SBRT is an important one.
JCOG2211 is poised to make history in the field of re-irradiation for spinal metastases.
Physicians worldwide, including myself, are closely following its results.

SC.24, SABR-COMET, SABR-5などの試験を通じて、私たちの研究グループはSBRTの有用性を示してきました。
我々、放射線治療医はクリニカルクエッションを一つ一つ解決していく必要があります。
中でも、再照射SBRTは重要なトピックの一つです。
JCOG2211は新たな歴史を作ろうとしており、私だけでなく世界中の医師がその結果に注目しています。